NYSEAMERICAN:BTX - BioTime Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.40 +0.10 (+4.35 %) (As of 07/19/2018 01:21 AM ET)Previous Close$2.30Today's Range$2.27 - $2.4152-Week Range$1.98 - $3.16Volume704,500 shsAverage Volume436,276 shsMarket Capitalization$338.75 millionP/E RatioN/ADividend YieldN/ABeta1.96 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California. Receive BTX News and Ratings via Email Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryBiotechnology SectorMedical SymbolNYSEAMERICAN:BTX CUSIP09066L10 Webwww.biotimeinc.com Phone+1-510-5213390 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins828.55% Return on Equity30.68% Return on Assets27.02% Miscellaneous EmployeesN/A Outstanding Shares126,870,000Market Cap$338.75 BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions What is BioTime's stock symbol? BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX." How were BioTime's earnings last quarter? BioTime, Inc. (NYSEAMERICAN:BTX) released its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The biotechnology company earned $0.70 million during the quarter, compared to the consensus estimate of $0.83 million. BioTime had a net margin of 828.55% and a return on equity of 30.68%. View BioTime's Earnings History. When is BioTime's next earnings date? BioTime is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for BioTime. What price target have analysts set for BTX? 1 analysts have issued twelve-month target prices for BioTime's shares. Their predictions range from $8.00 to $8.00. On average, they expect BioTime's share price to reach $8.00 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Ratings for BioTime. What is the consensus analysts' recommendation for BioTime? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting BioTime? BioTime saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 10,530,648 shares, an increase of 5.8% from the June 15th total of 9,949,118 shares. Based on an average trading volume of 456,480 shares, the short-interest ratio is currently 23.1 days. Currently, 8.4% of the shares of the company are sold short. View BioTime's Current Options Chain. Who are some of BioTime's key competitors? Some companies that are related to BioTime include Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT) and Monash IVF Group (MVF). Who are BioTime's key executives? BioTime's management team includes the folowing people: Dr. Michael D. West, Co-CEO & Director (Age 65)Mr. Aditya P. Mohanty, Co-CEO, Pres & Director (Age 51)Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 47)Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 64) Has BioTime been receiving favorable news coverage? News coverage about BTX stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. BioTime earned a news impact score of 0.09 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.32 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. How do I buy shares of BioTime? Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioTime's stock price today? One share of BTX stock can currently be purchased for approximately $2.40. How big of a company is BioTime? BioTime has a market capitalization of $338.75 million. How can I contact BioTime? BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390. MarketBeat Community Rating for BioTime (NYSEAMERICAN BTX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 139 (Vote Outperform)Underperform Votes: 136 (Vote Underperform)Total Votes: 275MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?